… on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program features and updates: ProQR to … Axiomer®: ProQR will introduce its novel, proprietary RNAediting platform technology. Art Levin, Ph.D., an …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a … review of the Company’s clinical-stage programs and RNAediting technology platforms. A webcast replay of the …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board. Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the Company’s …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … excited by the potential of our next-generation Axiomer RNAediting technology. In addition to using this platform to …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … Annual Conference A presentation titled “Therapeutic RNAediting by Axiomer ® editing oligonucleotides” by Janne …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced that it has …
… two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets … collaboration are not disclosed. ProQR is developing its RNA platform technology in areas of ophthalmology, cystic … look forward to collaborating with ProQR and its exciting RNAediting technologies.” About ProQR ProQR Therapeutics is …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today announced the pricing …